Happy girl on board of sailing yacht have a fun.
November 13, 2020

Beyond Anti-VEGF: Novel Therapies Show Promise in DME

For retinal diseases like diabetic macular edema (DME), repeated intravitreal anti-VEGF injections are the primary therapy. However, anti-VEGFs are not…

3D art   Holy Grail
October 20, 2020

Extended-Release Implants: Re-Vana Therapeutics’ Quest for an Anti-VEGF Grail

During the 38th Congress of the ESCRS, PIE magazine CEO Matt Young had a chance to speak with Michael O’Rourke, CEO of Re-Vana Therapeutics and a 25-year veteran in the ophthalmic industry. Together, they traced Mr. O’Rourke’s winding route to Re-Vana and explored his motivations that led him to the company and its major modus operandi.

Discover our fascinating content at issuu